https://noventure.com/specialist-doctor-shares-tips-for-your-healthy-growth-and-care/2025-10-17T12:48:56+00:00https://noventure.com/uegweek-2017-the-25th-united-european-gastroenterology-week/2025-10-17T13:06:57+00:00https://noventure.com/pharmavenue-palma-de-mallorca/2025-10-17T13:03:51+00:00https://noventure.com/fnm-2018/2025-10-17T13:06:14+00:00https://noventure.com/gastro-update-europe-2019/2025-10-17T14:16:50+00:00https://noventure.com/cphi-2019/2025-10-17T13:12:18+00:00https://noventure.com/cphi/2025-10-17T14:16:40+00:00https://noventure.com/vitafoods-2023/2025-10-17T13:25:02+00:00https://noventure.com/eau-2023/2025-10-17T13:27:52+00:00https://noventure.com/europlx-2023/2025-10-17T14:16:32+00:00https://noventure.com/espghan-2023/2025-10-17T13:33:43+00:00https://noventure.com/ewma-2023/2025-10-17T13:36:18+00:00https://noventure.com/europharm-2023/2025-10-17T13:39:34+00:00https://noventure.com/europlx-82/2025-10-17T14:16:23+00:00https://noventure.com/vitafoods-2024/2025-10-17T14:15:57+00:00https://noventure.com/europlx-84/2025-10-17T13:51:49+00:00https://noventure.com/ipls-2023/2025-10-17T13:54:11+00:00https://noventure.com/cphi-2/2025-10-17T14:16:14+00:00https://noventure.com/pharmasynergy-otc/2025-10-17T14:19:36+00:00https://noventure.com/europlx-84-2/2025-10-17T14:21:48+00:00https://noventure.com/pharmasynergy-otc-2/2025-10-17T14:24:42+00:00https://noventure.com/europlx-83/2025-10-17T14:26:55+00:00https://noventure.com/nutraceuticals/2025-10-17T14:28:44+00:00https://noventure.com/infarma/2025-10-17T14:31:20+00:00https://noventure.com/eau-2024/2025-10-17T14:33:44+00:00https://noventure.com/europharm/2025-10-17T14:35:31+00:00https://noventure.com/europlx-85/2025-10-17T14:38:00+00:00https://noventure.com/cphi-2024/2025-10-17T14:40:21+00:00https://noventure.com/vitafoods-2025/2025-10-17T14:42:23+00:00https://noventure.com/europlx-86/2025-10-20T06:29:49+00:00https://noventure.com/espghan-2025/2025-10-20T06:35:35+00:00https://noventure.com/eau-2025/2025-10-20T06:39:39+00:00https://noventure.com/europharm-international-business-meeting-2025/2025-10-20T06:42:02+00:00https://noventure.com/europlx-87/2025-10-20T06:44:21+00:00https://noventure.com/europlx-88/2025-10-20T06:46:41+00:00https://noventure.com/cphi-2025/2025-10-20T06:49:23+00:00https://noventure.com/xyloglucan-for-the-treatment-of-acute-diarrhea-results-of-a-randomized-controlled-open-label-parallel-group-multicentre-national-clinical-trial/2025-10-20T06:52:10+00:00https://noventure.com/gelatin-tannate-ameliorates-acute-colitis-in-mice-by-reinforcing-mucus-layer-and-modulating-gut-microbiota-composition-emerging-role-for-gut-barrier-protectors-in-ibd/2025-10-20T07:16:35+00:00https://noventure.com/xyloglucan-hibiscus-and-propolis-for-the-prevention-of-urinary-tract-infections-results-of-in-vitro-studies/2025-10-20T07:18:57+00:00https://noventure.com/efficacy-and-safety-of-a-medical-device-versus-placebo-in-the-early-treatment-of-patients-with-symptoms-of-urinary-tract-infection-a-randomized-controlled-trial/2025-10-20T07:20:37+00:00https://noventure.com/a-new-approach-to-the-treatment-of-uncomplicated-cystitis-results-of-a-randomized-placebo-controlled-clinical-trial/2025-10-20T07:22:21+00:00https://noventure.com/undissociated-gelatine-tannate-and-xyloglucan-prevent-gut-leakiness-and-mucosal-inflammation-induced-by-lps-insights-in-the-mechanism-of-action/2025-10-20T07:25:07+00:00https://noventure.com/xyloglucan-for-the-treatment-of-acute-diarrhea-results-of-a-randomized-controlled-open-label-parallel-group-multicentre-national-clinical-trial-2/2025-10-20T07:26:49+00:00https://noventure.com/the-therapeutic-management-of-gut-barrier-leaking-the-emerging-role-for-mucosal-barrier-protectors/2025-10-20T07:28:17+00:00https://noventure.com/barrier-enforcing-measures-as-treatment-principle-in-allergic-rhinitis-a-systematic-review/2025-10-20T07:30:48+00:00https://noventure.com/glycoconjugates-and-glycomimetics-as-microbial-anti-adhesives/2025-10-20T07:34:03+00:00https://noventure.com/tight-junctions-from-simple-barriers-to-multifunctional-molecular-gates/2025-10-20T07:38:18+00:00https://noventure.com/biopolymeric-mucin-and-synthetic-polymer-analogs-their-structure-function-and-role-in-biomedical-applications/2025-10-20T07:40:14+00:00https://noventure.com/the-mucosal-barrier-at-a-glance/2025-10-20T07:41:59+00:00https://noventure.com/tight-juction-related-human-diseases/2025-10-20T07:43:12+00:00https://noventure.com/recurrent-urinary-tract-infections-in-women-risk-factors-etiology-pathogenesis-and-prophylaxis-future-microbiology-published-online-27-feb-2017/2025-10-20T07:45:35+00:00https://noventure.com/new-insights-into-the-mechanism-of-action-of-gelatine-tannate-for-acute-diarrhoea-part-2-antibacterial-activity/2025-10-20T07:47:09+00:00https://noventure.com/prospective-observational-study-on-adults-with-acute-diarrhoea-treated-with-gelatine-tannate/2025-10-20T07:48:50+00:00https://noventure.com/gelatine-tannate-for-the-treatment-of-acute-diarrhoea-in-adults/2025-10-20T07:50:19+00:00https://noventure.com/regulation-of-tight-junction-permeability-by-intestinal-bacteria-and-dietary-components/2025-10-20T07:51:45+00:00https://noventure.com/allergy-as-an-epithelial-barrier-disease/2025-10-20T07:53:28+00:00https://noventure.com/antibiofilm-polysaccharides/2025-10-20T07:55:03+00:00https://noventure.com/evaluation-of-reticulated-gelatin-hibiscus-propolis-against-intestinal-commensal-species-commonly-associated-with-urinary-tract-infections-future-microbiology-published-online-3-march-2017/2025-10-20T07:56:28+00:00https://noventure.com/glycans-as-legislators-of-host-microbial-interactions-spanning-the-spectrum-from-symbiosis-to-pathogenicity/2025-10-20T07:57:59+00:00https://noventure.com/prospective-observational-study-on-infants-and-children-with-acute-diarrhoea-treated-with-gelatine-tannate/2025-10-20T07:59:43+00:00https://noventure.com/a-comparative-analysis-of-response-to-ors-oral-rehydration-solution-vs-ors-gelatine-tannate-in-two-cohorts-of-paediatric-patients-with-acute-diarrhoea/2025-10-20T08:02:04+00:00https://noventure.com/tasectan-gelatine-tannate-for-the-treatment-of-acute-gastroenteritis-in-children-preliminary-results-from-a-study-conducted-to-evaluate-its-efficacy-and-safety/2025-10-20T08:03:48+00:00https://noventure.com/severe-diarrhea-in-a-4-month-old-baby-girl-with-acute-gastroenteritis-a-case-report-and-review-of-the-literature/2025-10-20T08:06:04+00:00https://noventure.com/gelatin-tannate-as-treatment-for-acute-diarrhea-in-children-a-prospective-randomized-parallel-study/2025-10-20T08:07:47+00:00https://noventure.com/efficacy-and-safety-of-gelatine-tannate-for-the-treatment-of-acute-gastroenteritis-in-children-protocol-of-a-randomised-controlled-trial/2025-10-20T08:09:06+00:00https://noventure.com/evaluation-of-gelatin-tannate-against-symptoms-of-acute-diarrhea-in-pediatric-patients/2025-10-20T08:34:36+00:00https://noventure.com/the-effect-of-gelatin-tannate-in-acute-diarrhea-in-children/2025-10-20T08:36:23+00:00https://noventure.com/xyloglucan-for-the-treatment-of-acute-gastroenteritis-in-children-results-of-a-randomized-controlled-clinical-trial/2025-10-20T08:38:10+00:00https://noventure.com/xyloglucan-for-the-treatment-of-acute-gastroenteritis-in-children-results-of-a-randomized-controlled-open-label-parallel-group-multicentre-national-clinical-trial/2025-10-20T08:39:46+00:00https://noventure.com/gelatin-tannate-and-tyndallized-probiotics-a-novel-approach-for-treatment-of-diarrhea/2025-10-20T08:41:40+00:00https://noventure.com/scientific-publicationregulation-of-tight-junctions-in-upper-airway-epithelium/2025-10-20T08:43:21+00:00https://noventure.com/gelatin-tannate-a-selective-biofilm-forming-gut-mucoprotectant-for-acute-gastroenteritis-in-children-a-short-narrative-review/2025-10-20T08:45:14+00:00https://noventure.com/new-publication-on-tasectan-duo/2025-10-20T08:47:06+00:00https://noventure.com/congresses-noventures-remarkable-participation-at-espghan-congress-may-10-13-2017-prague/2025-10-20T08:49:43+00:00https://noventure.com/the-outer-mucus-layer-hosts-a-distinct-intestinal-microbial-niche/2025-10-20T08:51:16+00:00https://noventure.com/intestinal-goblet-cells-and-mucins-in-health-and-disease-recent-insights-and-progress/2025-10-20T08:52:54+00:00https://noventure.com/new-insights-into-the-mechanism-of-action-of-gelatine-tannate-for-acute-diarrhoea-part-1-film-forming-effect/2025-10-20T08:54:16+00:00https://noventure.com/undissociated-gelatine-tannate-reduces-intestinal-leakiness-and-mucosa-inflammation-by-forming-a-protective-biofilm-results-from-in-vitro-and-in-vivo-studies/2025-10-20T08:55:56+00:00https://noventure.com/effect-of-utipro-containing-xyloglucan-gelatin-against-escherichia-coli-invasion-of-intestinal-epithelial-cells-results-of-an-in-vitro-study/2025-10-20T08:57:16+00:00https://noventure.com/corporate-press-release-noventure-and-rfsu-enter-into-agreement-to-commercialize-utipro-plus-across-nordic-countries/2025-10-20T08:58:39+00:00https://noventure.com/noventures-participation-to-2017-eau/2025-10-20T09:00:36+00:00https://noventure.com/irritable-bowel-syndrome/2025-10-20T09:02:00+00:00https://noventure.com/management-of-acute-diarrhoea/2025-10-20T09:03:19+00:00https://noventure.com/new-partnership-xilaplus-af-in-turkey/2025-10-20T09:05:08+00:00https://noventure.com/new-scientific-communication-on-utipro-plus/2025-10-20T09:07:11+00:00https://noventure.com/new-scientific-publication-on-tasectan-duo/2025-10-20T09:09:01+00:00https://noventure.com/the-role-of-mucoprotectants-in-the-management-of-gastrointestinal-disorders/2025-10-20T09:10:50+00:00https://noventure.com/tasectan-duo-launched-in-austria/2025-10-20T09:12:11+00:00https://noventure.com/utipro-plus-launched-in-israel/2025-10-20T09:13:45+00:00https://noventure.com/utipro-plus-launched-in-france/2025-10-20T09:15:28+00:00https://noventure.com/new-scientific-publication-on-mucoprotection-and-diarrheal-processes/2025-10-20T09:17:08+00:00https://noventure.com/corporate-press-release-noventure-and-laboratorios-salvat-enter-into-agreement-to-commercialise-innovative-medical-device-in-spain-and-portugal-for-rhinitis-and-rhinosinusitis/2025-10-20T09:18:45+00:00https://noventure.com/noventure-welcomes-new-partners-to-expand-the-presence-of-its-products-in-new-territories/2025-10-20T09:28:22+00:00https://noventure.com/noventure-is-delighted-to-announce-the-launch-of-tasectan-in-russia-by-its-partner-company-jadran-under-the-umbrella-brand-adiarin/2025-10-20T09:30:31+00:00https://noventure.com/antibiotic-resistant-infection-treatment-costs-have-doubled-since-2002-now-exceeding-2-billion-annually/2025-10-20T09:32:18+00:00https://noventure.com/noventures-participation-in-2018-eau-congress/2025-10-20T09:34:52+00:00https://noventure.com/new-scientific-evidence-reinforces-usefulness-of-the-mucoprotective-approach/2025-10-20T09:36:11+00:00https://noventure.com/noventure-presents-its-pediatric-range-at-the-51st-espghan-annual-meeting-in-geneva-09-12-may-2018/2025-10-20T09:37:57+00:00https://noventure.com/news-on-noventure-participation-in-2018-eaaci-in-munich/2025-10-20T09:39:34+00:00https://noventure.com/new-scientific-publication-on-rhinosectan/2025-10-20T09:40:55+00:00https://noventure.com/rhinosectan-spray-containing-xyloglucan-on-the-ciliary-function-of-the-nasal-respiratory-epithelium-results-of-an-in-vitro-study/2025-10-20T09:42:16+00:00https://noventure.com/efficacy-of-gelatin-tannate-for-acute-diarrhea-in-children-a-systematic-review-and-meta-analysis/2025-10-20T09:43:51+00:00https://noventure.com/xilaplus-launched-in-france-by-therabel/2025-10-20T09:45:37+00:00https://noventure.com/tasectan-launched-in-croatia-by-jgl/2025-10-20T09:47:03+00:00https://noventure.com/xyloglucan-a-plant-polymer-with-barrier-protective-properties-over-the-mucous-membranes-an-overview/2025-10-20T09:50:12+00:00https://noventure.com/news-on-noventure-participation-at-eau-2019-in-barcelona/2025-10-20T09:52:09+00:00https://noventure.com/utipro-plus-launched-in-finland/2025-10-20T09:53:30+00:00https://noventure.com/utipro-plus-af-available-for-launch/2025-10-20T09:55:11+00:00https://noventure.com/xyloglucan-hibiscus-and-propolis-to-reduce-symptoms-and-antibiotics-use-in-recurrent-utis-a-prospective-study/2025-10-20T09:56:42+00:00https://noventure.com/urinary-tract-infections-in-the-elderly-a-review-of-disease-characteristics-and-current-treatment-options/2025-10-20T09:58:31+00:00https://noventure.com/a-new-publication-confirms-the-role-of-xyloglucan-as-a-mucosa-protector-in-the-management-of-urinary-tract-infections/2025-10-20T10:00:35+00:00https://noventure.com/utipro-plus-webinar-session/2025-10-20T10:02:28+00:00https://noventure.com/new-publication-for-utipro-plus/2025-10-20T10:04:05+00:00https://noventure.com/noventure-grants-pharmaforce-exclusive-distribution-right-for-its-product-tasectan-af-in-the-countries-denmark-sweden-finland-and-norway/2025-10-20T10:05:35+00:00https://noventure.com/launch-of-tasectan-af-in-finland-and-sweden/2025-10-20T10:07:48+00:00https://noventure.com/utipro-plus-launched-in-denmark/2025-10-20T10:14:15+00:00https://noventure.com/launch-of-tasectan-af-in-denmark/2025-10-20T10:17:31+00:00https://noventure.com/partner-pamex-uk/2025-10-20T10:19:37+00:00https://noventure.com/partner-medexport-utipro-plus-af-kazakhstan/2025-10-20T10:21:12+00:00https://noventure.com/partner-medexport-utipro-plus-af-kazakhstan-2/2025-10-20T10:22:45+00:00https://noventure.com/advantages-of-gel-oral-rehydration-solutions-ors-for-the-management-of-acute-diarrhea-an-update/2025-10-20T10:25:13+00:00https://noventure.com/listado-de-investigadores/2025-10-20T10:37:53+00:00https://noventure.com/a-new-class-of-non-drug-treatments-for-rhinitis-of-various-origins-is-gaining-momentum-among-them-xyloglucan-stands-out-as-a-natural-substance-with-a-well-defined-mode-of-action/2025-10-20T10:46:57+00:00https://noventure.com/gelatin-tannate-for-acute-childhood-gastroenteritis-a-randomized-single-blind-controlled-trial/2025-10-20T10:48:34+00:00https://noventure.com/the-combination-of-oligo-and-polysaccharides-and-reticulated-protein-for-the-control-of-symptoms-in-patients-with-irritable-bowel-syndrome-results-of-a-randomised-placebo-controlled-double-blind/2025-10-20T10:51:05+00:00https://noventure.com/rhinosectan-launched-in-spain/2025-10-20T10:53:11+00:00https://noventure.com/aga-abstracts-tu1254-protective-effect-of-mucoprotectants-and-prebiotic-combination-on-gut-barrier-impairment-and-visceral-hypersensitivity-induced-by-an-acute-stress-in-rat/2025-10-20T10:55:14+00:00https://noventure.com/congresses-noventure-participates-at-the-third-edition-of-fnm/2025-10-20T10:56:56+00:00https://noventure.com/a-randomized-controlled-trial-comparing-a-xyloglucan-based-nasal-spray-with-saline-in-adults-with-symptoms-of-rhinosinusitis/2025-10-20T10:59:12+00:00https://noventure.com/gelatin-tannate-versus-other-antidiarrheal-medication-in-children-with-acute-gastroenteritis-a-retrospective-observational-study/2025-10-20T11:00:53+00:00https://noventure.com/uncomplicated-urinary-tract-infection-in-adults-noventure-new-publication/2025-10-20T11:02:34+00:00https://noventure.com/we-are-proud-to-announce-the-publication-of-the-clinical-trial-randomized-placebo-controlled-trial-of-xyloglucan-and-gelose-for-the-treatment-of-acute-diarrhea-in-children/2025-10-20T11:04:20+00:00https://noventure.com/utipro-plus-af-strengthens-its-presence-in-europe/2025-10-20T11:05:59+00:00https://noventure.com/noventure-is-proud-to-announce-the-launch-of-xilaplus-in-estonia-latvia-and-lithuania-by-our-partner-company-miecys/2025-10-20T11:07:46+00:00https://noventure.com/first-launch-of-utipro-plus-af-in-europe/2025-10-20T11:10:00+00:00https://noventure.com/press-release-noventure-acquires-ulkox-and-oleoabrax-two-medical-devices-based-on-patented-new-wound-healing-technology/2025-10-20T11:13:11+00:00https://noventure.com/first-publication-for-ole-hydrogel/2025-10-20T11:14:38+00:00https://noventure.com/impact-of-covid-19-on-uti-and-antibiotic-stewardship-t-cai-et-al-on-uro-2022/2025-10-20T11:16:43+00:00https://noventure.com/publication-of-first-clinical-evidence-for-eho-85-hydrogel/2025-10-20T11:18:07+00:00https://noventure.com/second-publication-for-ole-hydrogel/2025-10-20T11:19:45+00:00https://noventure.com/do-you-know-noventure/2025-10-20T11:22:08+00:00https://noventure.com/new-publication-for-utipro-plus-utipro-plus-af/2025-10-20T11:23:33+00:00https://noventure.com/new-publication-on-the-mode-of-action-of-mucoprotectants-gelatin-tannate-and-xyloglucan-show-similar-effectivity-on-preventing-cholera-toxin-induced-diarrhea-in-experimental-studies1/2025-10-20T11:25:06+00:00https://noventure.com/new-publication-on-recurrent-uti-qa-on-clinical-practice1/2025-10-20T11:26:54+00:00https://noventure.com/new-publication-on-the-benefits-of-our-hydrogel-eho-85-containing-olive-leaves-extract-in-accelerating-early-wound-healing/2025-10-20T11:28:22+00:00https://noventure.com/new-publication-for-utipro-plus-utipro-plus-af-the-utiswiss-study/2025-10-20T11:29:35+00:00https://noventure.com/utipro-plus-af-reaches-central-asia/2025-10-20T11:31:38+00:00https://noventure.com/tasectan-mdr-approved/2025-10-20T11:33:10+00:00https://noventure.com/new-publication-on-hydrogel-eho-85-in-difficult-to-heal-wounds/2025-10-20T11:34:55+00:00https://noventure.com/new-publication-on-hydrogel-eho-85-in-anal-fissures/2025-10-20T11:36:43+00:00https://noventure.com/partner-devicare-s-l/2025-10-20T11:39:05+00:00https://noventure.com/publication-on-the-antioxidant-and-wound-healing-properties-of-eho-85/2025-10-20T11:40:52+00:00https://noventure.com/gel-eho-85-publications/2025-10-20T11:42:58+00:00https://noventure.com/new-publication-on-good-results-with-eho-85-hydrogel-compared-to-products-commonly-used-in-wound-healing/2025-10-20T11:44:57+00:00https://noventure.com/tasectan-and-xilaplus-in-the-new-german-gpgn-guidelines/2025-10-20T11:47:08+00:00